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Natural killer (NK) cells are innate immune lymphocytes critical for host defense against
viral infection and surveillance against malignant transformation. MicroRNAs (miRNAs) are
a family of small, non-coding RNAs that regulate a wide variety of cellular processes.
Recent advances have highlighted the importance of miRNA-mediated post-transcriptional
regulation in NK cell development, maturation, and function. This review focuses on
several facets of this regulatory mechanism in NK cells: (1) the expressed NK cell miRNA
transcriptome; (2) the impact of total miRNA deﬁciency on NK cells; (3) the role of speciﬁc
miRNAs regulating NK cell development, survival, and maturation; (4) the intrinsic role
of miRNAs regulating NK cell function, including cytokine production, proliferation, and
cytotoxicity; and (5) the role of NK cell miRNAs in disease. Currently our knowledge of how
miRNAs regulate NK cell biology is limited, and thus we also explore key open questions in
the ﬁeld, as well as approaches and techniques to ascertain the role of individual miRNAs
as important molecular regulators.
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INTRODUCTION
Natural killer (NK) cells are innate immune lymphocytes that
develop from the common lymphoid progenitor in the bone mar-
row; however, NK cells are deﬁned by a unique biological program
that is distinct from the adaptive T and B lymphocytes which
develop from that same progenitor (Yokoyama et al., 2004). NK
cell development proceeds through a series of intermediates that
are dependent on growth factors and cytokines, distinct from B
and T cell development, to support their development and home-
ostasis, especially IL-15 (Colucci et al., 2003; Freud and Caligiuri,
2006). Furthermore, NK cells reconstitute after hematopoietic
stem cell transplantation more rapidly than other lymphocytes
(Storek et al., 2008), further attesting to their uniqueness as a lym-
phoid lineage. However, although the distinctions between NK
cells and other lymphocytes are well known, the molecular events
and programs that deﬁne NK cells are incompletely understood,
and remain an important area of NK cell investigation.
In mice, NK cells are identiﬁed as lymphocytes that express
two activating receptors: NK1.1 (C57Bl/6) and NKp46 (virtually
all mouse background strains), and lack CD3 and CD19 expres-
sion (Colucci et al., 2003). In humans, NK cells are distinguished
by their expression of CD56, and a lack of CD3 and rearranged
T cell receptors. NK cells begin their development in the bone
marrow, where they are subject to an education process, in which
the NK cells are licensed to full functionality by becoming tuned
to the “normal” levels of cell surface ligands, primarily major
histocompatibility complex (MHC) class I or related molecules
(Joncker and Raulet, 2008; Jonsson and Yokoyama, 2009). Murine
NK cells undergo further maturation in peripheral lymphoid
organs, marked by expression of CD27, CD11b, and CD43
(Chiossone et al., 2009). Human NK cells in the periphery may
further be divided into subsets by their expression of CD56 and
CD16 (FCγRIIIa): the functionally and developmentally distinct
CD56bright and CD56dim populations (Caligiuri, 2008).
Mature peripheralNK cells defend the host frompathogens and
mediate anti-tumor responses (Yokoyama et al., 2004; Caligiuri,
2008; Di Santo, 2008; Lanier, 2008). One way that NK cells pro-
tect the host is by detecting abnormal surface receptor repertoires
on target cells, through loss of self-deﬁning proteins and/or gain
of abnormal or induced self-proteins. Typical inhibitory NK cell
receptor ligands include MHC class I molecules, which are often
down-regulated on target tumor and infected cells, and “stress”
ligands such as retinoic acid early inducible-I (Rae-I) and UL16
binding protein 1 (ULBP1), which can activate NK cells and are
often up-regulated on these target cells. It is the relative levels
of these inhibitory and activating signals that determine whether
or not the NK cell is triggered to respond to a potential target
cell (Lanier, 2005; Bryceson and Long, 2008). Once triggered,
NK cells then mediate cytotoxicity against these cells through the
release of cytotoxic granules, as well as produce various cytokines
and chemokines that inﬂuence the developing immune response
(Vivier et al., 2008). In addition to responding to ligands on target
cells, NK cells express a number of cytokine receptors and can be
activated or primed by pro-inﬂammatory cytokines for optimal
effector function. Cytokine activation can also override inhibition
mediated by some cell surface signals, and thus represents another
important signal for NK cell functional capacity (Fehniger et al.,
2007; Lee et al., 2007; Lucas et al., 2007; Caligiuri, 2008; Chaix
et al., 2008).
Currently, our understanding of the basic molecular mecha-
nisms regulating NK cell development, maturation, survival, and
function is incomplete. A number of transcription factors have
been identiﬁed that contribute to NK cell development and func-
tion (Ramirez and Kee, 2010; Hesslein and Lanier, 2011). Recently,
studies have highlighted the role of post-transcriptional control,
especially microRNAs (miRNAs), on the NK cell molecular pro-
gram (Fehniger et al., 2007; Bezman et al., 2010; Sullivan et al.,
2012). In this review, we highlight the current state of the ﬁeld in
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miRNA-mediated control of NK cell development, survival, mat-
uration, with a focus on global and speciﬁc miRNA deﬁciency and
over-expression. As our knowledge of the molecular programs,
including miRNAs, that regulate NK cells increases, this will lead
to identiﬁcation of novel molecules and pathways that may be
manipulated to enhance or attenuate NK cell function.
MicroRNAs
MicroRNAs are non-coding RNAs, many of which are highly
conserved and regulate numerous cellular functions. miRNA
repression is mediated primarily by targeting sites in the 3′UTR
of mRNAs, leading to translational inhibition or causing mRNA
degradation (He and Hannon, 2004). One report has indicated
that some miRNAs can increase protein expression via binding to
the 5′UTR (Vasudevan et al., 2007), but it remains unclear whether
this is widely applicable.
Over 1,000 miRNA genes are predicted in humans and mice.
miRNAs can be processed in a variety of ways (Winter et al.,
2009), but the canonical pathway (Figure 1) consists of tran-
scription from genomic sequence as long primary (pri-miRNA)
transcripts that are “cropped” by the Drosha/Dgcr8 complex into
precursor miRNAs (pre-miRNA) that have a characteristic stem-
loop structure (Kim, 2005). The pre-miRNA is exported to the
cytoplasm where it is “diced” by the Dicer complex (including
Dicer1) into a mature 19–26 nucleotide miRNA. The mature
miRNA is loaded into the RNA-induced silencing complex (RISC)
that includes the Argonaute proteins, and thereby directs down-
regulation of protein levels (Filipowicz et al., 2008; Liu, 2008; Wu
and Belasco, 2008). While the exact mechanism of protein reduc-
tion remains controversial, it is likely that it occurs through both
RNA degradation and translational repression pathways, perhaps
with different miRNAs contributing to each pathway in differ-
ent proportions. While perfect miRNA:mRNA complementarity
(common in C. elegans) can lead to direct mRNA degradation,
most miRNAs in higher organisms are imperfectly matched, and
lead to mRNA degradation through deadenylation and decapping
methods (Liu, 2008). Both processes are mediated by the “stem”
of the “stem-loop,” the critical segment of the miRNA gene.
The role of miRNA-mediated regulation in antigen-speciﬁc T
and B lymphocytes is well characterized. In these cells, develop-
ment, survival, and function have been found to be controlled
by miRNAs, data which are clearly supported by mouse models
of miRNA gain- and loss-of-function (O’Connell et al., 2010b).
While the data supporting critical regulation of NK cells by
miRNAs are more exiguous (Di Santo, 2008), this review syn-
thesizes recent studies that have provided the ﬁrst insights into
the expressed mouse and human NK cell miRNA transcriptome
and mechanisms whereby miRNAs regulate NK cell development,
homeostasis, and functional responses.
THE NK CELL microRNA TRANSCRIPTOME
In contrast to T and B lymphocytes, there are few studies examin-
ing themiRNAproﬁles of human ormouseNK cells. Themajority
of studies that include NK cell expression data have focused on
lymphocyte-wide comparisons, with an emphasis on identifying
miRNAs with cell-speciﬁc functions (Landgraf et al., 2007; Rossi
et al., 2011; Allantaz et al., 2012). As a result, many of these studies
utilize miRNA microarrays or Sanger sequencing of small RNA
clones. While these approaches provide the coverage necessary
for identifying miRNA “signatures,” there is comparatively less
FIGURE 1 | Summary of canonical miRNA biogenesis and function.
DNA (1) is transcribed by PolII into the pri-miRNA (2), which is then further
processed by Drosha/DGCR8 into the pre-miRNA (3). This pre-miRNA is
exported from the nucleus through exportin 5, then processed by Dicer to the
mature miRNA duplex (4). This duplex is unwound, and one strand, the
mature miRNA, is loaded into the RISC complex (5), where it usually binds
imperfectly to a target mRNA and mediates RNA degradation and/or
translational repression.
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miRNA detection depth and and/or dynamic range relative to
unbiased next-generation small RNA sequencing. Additionally,
next-generation sequencing provides novel miRNA identiﬁcation,
although at the tradeoff of higher cost per sample. Ideally, any
accurate and reliable proﬁling data would utilize cross-platform
validation of multiple biological samples.
To date, three studies have utilized next-generation sequencing
to probe mouse or human NK cell miRNA expression (Figure 2).
We identiﬁed the resting and 24-h IL-15-activated proﬁle of
murine splenic NK cells (Fehniger et al., 2010). This revealed
that while >200 miRNAs were detectable in NK cells, the top
50 constituted >95% of the miRNA sequence content. The
miRNA expression proﬁle was supported by two independent
next-generation sequencingplatforms (Illumina andSOLiD),with
validation by qPCR and microarrays. Overall, the expression
of normalized miRNA read counts was similar between resting
and 24-h IL-15-activated NK cells, with a small number of miR-
NAs signiﬁcantly modulated, peaking around threefold. It will be
important to extend these proﬁling studies to different types of
mouse NK cells, including developmental and maturation inter-
mediates, NK cells from distinct tissue compartments, and in
the context of physiologic responses to infectious pathogens and
tumor cells. A larger,more robust set of miRNAexpression proﬁles
will also facilitate comparison to other lymphocytes, and iden-
tify NK cell miRNA signatures which likely contribute to an NK
cell-speciﬁc molecular program.
Two subsequent studies by Liu and colleagues and Wang and
colleagues reported the miRNA proﬁles of resting and interferon-
α (IFN-α; Wang et al., 2012), IL-2, IL-15, and IL-21 (Liu et al.,
2012) activated bulk CD56+CD3− human NK cells from periph-
eral blood. The resting human NK cell data sets show substantial
variation from each other, thus indicating that human diversity
may also be an important consideration during expression stud-
ies. Indeed, both groups that have reported human NK expression
include data from only one resting human sample, which limits
conclusions that can be drawn from comparing these particu-
lar data sets to each other. Additionally, the proﬁling from Wang
et al. (2012) is challenging to compare to the other studies, since
FIGURE 2 | Mouse and human NK cell miRNA expression.
(A)The top 30 miRNAs detected by Illumina sequencing in mouse
splenic NK cells (Fehniger et al., 2010). (B)Top expressed miRNAs
detected and enumerated by small RNA Illumina sequencing of resting
human CD56+CD3− in theWang et al.’s 2012 study. (C)Top expressed
miRNAs detected by small RNA Illumina sequencing in the Liu et al.’s 2012
study. TheWang et al.’s 2012 and Liu et al.’s 2012 data are limited to the
miRNAs reported in the published paper, since the numerical data
was not provided in supplemental ﬁles nor deposited in public databases.
Liu et al.’s 2012 data were estimated from graphs included in the original
paper. 1miRNA not reported in Liu et al. (2012). 2miRNA not reported inWang
et al. (2012).
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only the top 12 miRNAs were reported outside of their private
activation-based analysis. Following activation, human NK cells
appear to modestly up-regulate nearly half of all expressed miR-
NAs in response to IL-15, although these data rely on comparisons
of resting and activated cells from separate donors (Table 1).
The miRNAs that changed with activation demonstrated mini-
mal overlap, suggesting activation-speciﬁc modulation or donor
variation. Interestingly, NK cells activated with IFN-α respond by
down-regulating a number of miRNAs, suggesting that miRNA
changes are dependent on the mode of stimulation. Such global
changes in miRNA may also reﬂect time point of measurement or
normalization biases, since the absolute miRNA content of a cell
can remain unchanged even as other small RNA content increases.
Indeed, 12-h IFN-α-activated NK cells had a 2.5-fold increase in
non-miRNA small RNA content (Wang et al., 2012).
From the Fehniger et al.’s (2010) and Wang et al.’s (2012) data,
miRNA expression patterns common to both human and mouse
NK cells are evident, with miR-21 being the most highly expressed
miRNA in both studies. However, there are relative abundance
differences, even among highly expressed miRNAs. One poten-
tial conclusion is that miRNAs have species-speciﬁc expression
patterns in NK cells. However, such cross-study comparisons
of absolute abundance are difﬁcult, since the reported human
miRNA expression proﬁles were from peripheral blood NK cells
from a single human donor, and the mouse proﬁling focused
on splenic NK cells. Further, there may be technical differences
in alignment, sequence ﬁltering, and normalization. Contrast-
ing mouse and human NK cell miRNA expression will require
additional data from each species, ideally performed using similar
sequencing-analysis pipelines.
In summary, while the basic resting NK cell miRNA transcrip-
tomes have been reported, our knowledge remains incomplete in
both mouse and human NK cells, hampered in part by a lack of
extensive cross-platform validation across biological replicates. A
number of questions are yet to be answered. Do different subsets
Table 1 | Selected up- or down-regulated miRNAs during cytokine
activation of NK cells.
Fehniger et al.
(2010) (mouse)
Wang et al.
(2012) (human)
Liu et al. (2012)
(human)
Stimulation IL-15 IFN-α IL-2, IL-15, or
IL-21
Duration (hour) 24 12 or 24 36
Up-regulated mmu-miR-188-5p
mmu-miR-339-5p hsa-let-7b hsa-miR-15a
mmu-miR-19a hsa-miR-155
Down-regulated mmu-miR-223 hsa-miR-378
mmu-miR-26b hsa-miR-103 hsa-miR-1246
mmu-miR-181a hsa-miR-30e hsa-miR-331-3p
miRNAs were selected based on the following criteria: top threefold change
within the top 12 expressed miRNAs (Wang et al., 2012), signiﬁcant miRNAs
consistently changed by the listed stimulation (Liu et al., 2012), and top threefold
change (Fehniger et al., 2010).
(e.g., CD56bright and CD56dim) differ in their miRNA proﬁles?
Does maturation stage and mode of activation affect miRNA
expression? Do NK cells from different cell compartments (e.g.,
thymic, splenic, lung, intestine, liver, etc.) express different miR-
NAs? Do miRNAs differ between different innate lymphoid cells
(Spits and Di Santo, 2011)? Further studies are needed to under-
stand how miRNAs are induced in NK cells, the kinetics of miRNA
alterations, and the effects of perturbed miRNA expression on
target genes.
THE IMPACT OF TOTAL miRNA DEFICIENCY ON NK CELLS
Because many miRNAs are expressed by NK cells (Fehniger et al.,
2010), knockout of critical miRNA processing genes, including
Drosha/DGCR8 and Dicer1 (Figure 1) is one approach to study
the effects of “global loss” of miRNAs. The ﬁrst studies of miRNA
in lymphocytes utilized Dicer1 knockout mice to eliminate all
Dicer1-dependent miRNAs, and were focused on T cells (Muljo
et al., 2005; Chong et al., 2008). These studies reported that the
global knockout of miRNA led to increased IFN-γ production,
and increased activation, albeit with a severe reduction in cellu-
lar count and proliferation. Similarly, studies focused on NK cells
have found comparable results (Table 2), with a few important
differences.
The ﬁrst model to investigate the ramiﬁcations of small RNA
deletion in NK cells was an inducible (estrogen receptor, ER) Cre
model combined with LoxP-ﬂanked Dicer1 and DGCR8 alleles
reported by the Lanier laboratory (Bezman et al., 2010). This
strategy eliminated miRNAs in all cells in the mouse following
tamoxifen treatment. Focusing on the impact of this miRNA loss
on NK cells revealed increased NK cell apoptosis in the periphery,
combinedwith a selective loss of morematureCD11b+CD27− NK
cells, and a reduction in surface expression of the activating NK
cell receptor NKG2D. These ﬁndings were coupled with reduced
IFN-γ production and CD107a surface expression following stim-
ulation with anti-NK1.1, anti-Ly49H, and anti-NKp46, but not
stimulation with cytokines such as IL-12 and IL-18. The authors
therefore concluded that miRNAs are essential regulators of NK
cell development and immunoreceptor tyrosine-based activation
motif (ITAM)-based stimulation of NK cells. The authors also
found that miRNA-deﬁcient Ly49H+ NK cells robustly prolifer-
ated in response to murine cytomegalovirus (MCMV) infection,
but did not survive, and thus were not able to function in an effec-
tive NK cell MCMV response. However, these results may have
confounding factors inﬂuenced by the NK-extrinsic nature of the
ER-Cre model, which results in global mature miRNA loss in all
cells in the organism.
A study from our laboratory utilized a more speciﬁc Cre model
(restricted to lymphocytes) to investigate the results of Dicer1-
dependentmiRNA loss (Sullivan et al., 2012).Weused a hCD2-Cre
transgene (de Boer et al., 2003), which expresses Cre from the ear-
liest stages of NK cell development in the bone marrow. Thus,
in these experiments Dicer1 was removed from NK cells [marked
by concurrent yellow ﬂuorescent protein (YFP) expression (Sul-
livan et al., 2012)] during the earliest stages of development,
and in a lymphocyte-restricted fashion. While this method was
not completely NK cell speciﬁc, it removes many potential
confounders by providing Dicer1-competent hematopoietic and
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Table 2 | Summary of global miRNA-deficient (Dicer1−/−and DGCR8−/−) or over-expression (Eri1−/−) NK cells.
Sullivan et al. (2012) Bezman et al. (2010) Thomas et al. (2012)
Cre model hCD2-Cre ER-Cre Global knockout
Gene Dicerﬂ/ﬂ Dicerﬂ/ﬂ/DGCR8ﬂ/ﬂ Eril−/−
Effect on miRNAs ↓ ↓ ↑
Survival ↓ ↓ ∼
Proliferation ↓ ↓ ↓
# NK cells ↓* ↓* ↓*
IFN-γ production ↑ ↓! ↓!
CD107a ↑ ↓ ∼
Receptor repertoire alterations None observed ↓NKG2D Multiple, especially ↓Ly49H/D
MCMV response ↑IFN-γ production ∼IFN-γ production ↓Ly49H+ NK cells ∼IFN-γ production ↓Ly49H+ NK cells
In vitro cytotoxicity N/A N/A ∼
*In particular, at latest stages of NK cell maturation. !In response to activating (ITAM) receptor-mediated stimulation.
non-hematopoietic cells. Thismodel conﬁrmed the reduced num-
bers and percentages of NK cells shown in the Bezman et al.’s
(2010) study, and reduced in vitro survival and proliferation, indi-
cating that NK cell development and homeostasis are critically
regulated by miRNAs. However, in contrast to the Bezman et al.’s
(2010) study, hCD2-Cre × Dicer1ﬂ/ﬂ NK cells produced more
IFN-γ and had enhanced degranulation (CD107a surface expres-
sion) in response to multiple activating stimuli. These effects were
also apparent in Dicer1ﬂ/wt mice, showing that even decreased
Dicer1 levels can have a functional consequence on NK cell biol-
ogy. Further, these ﬁndings in hCD2-Cre mice were corroborated
by increased IFN-γ production in vivo during MCMV infection.
The different phenotypes in these models likely reﬂect different
Cre-excision speciﬁcity and timing. Recently, NK cell-speciﬁc Cre
models driven by theNKp46/Ncr1 promoter in a bacterial artiﬁcial
chromosome (BAC) transgene (Eckelhart et al., 2011), or knock-in
(Narni-Mancinelli et al., 2011) have been reported. Thus, the tools
are ﬁnally available to deﬁnitively evaluate the cell-intrinsic effects
of both global and speciﬁc miRNA loss- and gain-of-function in
NK cells.
Another study by Thomas et al. (2012) focused on Eri1, an
exoribonuclease that degrades miRNAs and thus functions as a
negative regulator of miRNA-mediated control, and the effects of
its loss on NK and T cells. The authors found that Eri1-deﬁcient
NK and T cells displayed an increase in total miRNA abundance.
NK cells seemed particularly susceptible to the effects of Eri1 loss,
and displayed decreased percentage and numbers, especially at
the latest stages of development. The Eri1-deﬁcient NK cells dis-
played an altered cell receptor repertoire, including altered Ly49H
expression. In addition, while Eri1−/− NK cells did not show a
defect in IFN-γ production in response to IL-12 and IL-18, they
produced less IFN-γ in response to ITAM-dependent activating
receptors. Eri1-deﬁcient NK cells also displayed decreased prolif-
eration in response to MCMV infection, with increased viral titers,
demonstrating the importance of Eri1 (probably due to miRNA
alterations) in the context of viral infection. While Eri1-deﬁcient
NK cells have changes in global miRNA expression and a clear
development, maturation and functional phenotype, one caveat
to these ﬁndings acknowledged by the authors is that other RNA
species are affected by Eri1, thereby providing alternative expla-
nations for the NK cell phenotype. In any case, this study clearly
implicates Eri1-mediated RNA processing in NK cell development
and functional responses, probably reﬂective of global miRNA
changes in NK cells.
Thus, the preponderance of evidence suggests that miRNAs
promote cellular survival, maturation, and proliferation, while
suppressing the production of key immune cytokines such as
IFN-γ. However, the study by Thomas et al. (2012) suggests that
miRNA-mediated repression of genes is required in both direc-
tions, i.e., increased miRNA expression can also affect NK cell
homeostasis, supporting a role of miRNAs as “tuners” of cellular
homeostasis. The effects of total miRNA elimination or increase
on speciﬁc functions of NK cells, however, are difﬁcult to extricate
from effects on survival, and thus studying the cell-intrinsic effects
of individual miRNAs in NK cells will, in the future, be a more
productive approach to identifying the effects, targets, and mech-
anisms of speciﬁc miRNAs. One key caveat to these global miRNA
alteration studies is that the models utilized are not NK cell spe-
ciﬁc and may affect progenitors and mature NK cells at different
points in development/differentiation, as well as cells that inter-
act with NK cells. Combining NK cell-speciﬁc Cre models that
are now available (Eckelhart et al., 2011; Narni-Mancinelli et al.,
2011) with miRNA ﬂoxed alleles will provide important conﬁr-
matory studies of how both global deﬁciency and speciﬁc miRNA
alterations regulate NK cell biology.
miRNA REGULATION OF NK CELL DEVELOPMENT
Like other hematopoietic cells, NK cells originate from stem cells
within the bone marrow. As they develop, they require the expres-
sion of a number of signaling proteins and transcription factors
essential for the NK lineage (Colucci et al., 2003; Yokoyama et al.,
2004; Di Santo, 2006; Freud and Caligiuri, 2006). As discussed
previously, Dicer1 deﬁciency in NK cells results in altered NK
cell development; however, few studies have examined the role
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of speciﬁc miRNAs. To date, two miRNAs and their targeted
molecules have been implicated in this process: miR-150 targeting
c-Myb, and miR-181a/b targeting NEMO-like kinase (NLK).
miR-150 is a lymphocyte-restricted miRNA, and its expression
correlates with cell maturity, suggesting a role in development
(Monticelli et al., 2005). In mice, miR-150 expression acts as a
ﬁne-tuner of B cell production through the targeting of c-Myb, a
transcription factor involved in hematopoiesis (Xiao et al., 2007;
Zhou et al., 2007). In contrast,miR-150over-expressiononlymod-
estly reduces mature T cell numbers, in part through c-Myb and
possibly Notch3, a receptor involved in thymocyte development
(Ghisi et al., 2011). Bezman et al. (2011) reported that miR-
150−/− mice have a deﬁciency of mature NK cells resulting from
defects inmaturation and proliferation, and additionally thatmice
over-expressing miR-150 had an accumulation of mature, hyper-
functional NK cells. This phenotype was mimicked by c-Myb+/−
mice, the putative target of miR-150.
Two miR-181 family members, miR-181a and miR-181b, are
also expressed in lymphocytes in a stage-speciﬁc manner. Over-
expression inmurinemodels results in increasedB cell (Chen et al.,
2004) and T cell numbers (Li et al., 2007). Using an in vitro NK
cell differentiation system, Cichocki et al. (2011) demonstrated
that miR-181 expression increases in parallel with the maturation
stages of human NK cells. In vitro differentiation of CD34+ pro-
genitor cells transduced by lentivirus engineered to over-express
miR-181a enhanced the development of CD56+ NK cells. One
possible mechanism for this effect is through targeting of NLK, a
negative regulator of theNotch pathway,which is essential for lym-
phocyte development. Notch signals have been shown to support
in vitro human NK cell differentiation (Bachanova et al., 2009;
Beck et al., 2009; Haraguchi et al., 2009), and this work demon-
strates a role for miR-181 family members in regulating NK cell
development, possibly through modulating NLK and Notch in
lymphoid or NK cell progenitors. It will be important to further
assess miR-181a/b, as well as other miRNAs that change in expres-
sion during NK cell maturation, for additional mRNA targets and
impact on NK cell development and maturation.
miRNA REGULATION OF NK CELL FUNCTION
Cytotoxicity is a major function of NK cells, and multiple stud-
ies have investigated miRNA regulation of this pathway. Work
on miRNAs regulating cytotoxicity has focused on the two major
granule proteins, granzyme B (GzmB) and perforin (Prf1). Stud-
ies from our laboratory identiﬁed that both GzmB and Prf1
mRNA transcript was readily produced in resting murine NK
cells, and was only modestly up-regulated following IL-15 acti-
vation (Fehniger et al., 2007). This was in contrast to protein levels
and cytotoxic capacity, which both increased dramatically dur-
ing activation, suggesting a post-transcriptional mechanism of
regulation.
Four recent studies have identiﬁed miRNAs regulating GzmB
and Prf1 in NK cells (Figure 3). In studies from our lab, miR-
223 was found to target the murine GzmB 3′UTR, and identiﬁed
as the most down-regulated miRNA following IL-15 treatment,
which we hypothesized could lead to increased GzmB production
after activation (Fehniger et al., 2010). However, NK cells from
miRNA-223−/− mice (Johnnidis et al., 2008) appear to express
FIGURE 3 | Schema of recent studies demonstrating the role of
miRNAs in repression of cytotoxicity by NK cells.
similar amounts of GzmB aswild typemice at baseline, and exhibit
levels of cytotoxicity similar to wild type controls, suggesting that
miR-223 alone does not play a non-redundant role in limiting
murine GzmB translation in resting mouse NK cells (Leong and
Fehniger, unpublished data). Additional studies are still needed to
determine the impact of miR-223 gain- and loss-of-function, in
combination with other miRNAs, in primary NK cells.
In a second study, Kim et al. (2011) used in vitro differentiated
human NK cells (CD34+ hematopoietic progenitors cultured for
several weeks inNK cell differentiating conditions) to demonstrate
that miR-27a-5p (miR-27a*) targeted the 3′UTRs of both GzmB
and Prf1. This group observed reduced GzmB and Prf1 protein
with miR-27a-5p over-expression in this system (Kim et al., 2011).
Activation with IL-15 paradoxically leads to up-regulation of this
miRNA, possibly serving as a negative feedback loop on GzmB
and Prf1 production. Indeed, inhibition of miR-27a-5p in these
differentiated NK cells resulted in enhanced in vitro killing and
tumor protection in a xenograft model. However, the miRNA and
mRNA expression of in vitro differentiated NK cells that result
from long-term culture with high levels of activating cytokines
may be signiﬁcantly different than freshly isolated primary human
NK cells. miR-27a-5p (miR-27a*) is expressed at very low levels
in resting mouse (Fehniger et al., 2010) and human NK cells (Liu
et al., 2012), suggesting a more limited role for this miRNA outside
of extensive cytokine activation or ex vivo culture. Conﬁrmatory
studies using freshly isolated NK cells would be helpful to verify
the role of miR-27a-5p outside the context of extensive ex vivo
culture.
In the third study, Gong et al. (2012) show a role for miR-30c-
1* in targeting HMBOX1 and regulating cytotoxicity. The authors
use the human NK cell line (NKL), and showed that stimulation
through NKG2D led to down-regulation of a number of miRNAs
(Gong et al., 2012). One of these miRNAs, miR-30c-1-3p (miR-
30c-1*), targeted HMBOX1, an inhibitory transcription factor of
cytokine secretion. Over-expression or inhibition of miR-30c-1-
3p resulted in altered killing against two hepatoma cell lines. As
in the previous study, it will be important to further elucidate the
role of miR-30c-1* in primary NK cells.
In the fourth study, Wang et al. (2012) demonstrate a role for
miR-378 and miR-30e in repressing baseline protein expression of
GzmB and Prf1, respectively. In contrast to the GzmB and Prf1
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suppression model of miR-27a-5p, mature miR-378 and miR-30e
expression is reduced upon IFN-α stimulation, releasing repres-
sion of GzmB and Prf1 and enhancing the cytotoxicity of NK cells.
Expression of both miRNAs was shown to be inversely correlated
with GzmB and Prf1 protein production. Further, nucleofection
of miRNA sponges against either miRNA-378 or miR-30e in NK-
92 cells led to enhanced cytotoxicity against K562 tumor targets.
Collectively, these studies provide evidence that cytotoxic effector
molecules, including GzmB and Prf1, can be modulated by NK
cell miRNAs. Since differences in 3′UTRs exist between human
and mouse GzmB and perforin, careful evaluation of each candi-
date miRNA in both species will be required to fully understand
its role in regulating NK cell cytotoxicity.
IFN-γ is a key immune cytokine produced by NK cells fol-
lowing activation. The regulation of its production is complex
and involves the integration of various signaling pathways (Vivier
et al., 2008) andmultiple layers of regulation (Young,1996). As one
form of regulation, IFN-γ is regulated post-transcriptionally via a
5′ pseudoknot and 3′ AU-rich elements, both of which can affect
the stability of the IFN-γ transcript (Khabar and Young, 2007).
Recently, miRNA-mediated regulation has also been reported.
However, due to the integrative nature of IFN-γ production,many
of these effects are indirect, instead mediating upstream signal-
ing components. For example, signal transducer and activator of
transcription 4 (STAT4), a key mediator of IL-12-induced signals,
was reported to be targeted by miR-132, miR-212, and miR-200a
(Huang et al., 2011). In addition, lentiviral over-expression of
miR-181a/b has been reported to increase human NK cell IFN-γ
production after stimulation with IL-12 and IL-18 production
(Cichocki et al., 2011). However, these cells were cultured for
14 days in IL-15, transduction efﬁciency and subset biology was
not presented, and thus the alterations may be inﬂuenced by the
changes that result from long-term culture. In T cells, multiple
miRNAs, including the miR-17∼92 cluster (Jiang et al., 2011) and
miR-21 (Lu et al., 2011b) have been shown to regulate the deci-
sion between T helper type 1 (Th1) and Th2 lineages, which has
an indirect effect on IFN-γ production. Three miRNA families
have been found to speciﬁcally target IFN-γ or genes immedi-
ately upstream of its induction in NK cells: miR-155, miR-29, and
miR-15/16.
miR-155 was discovered to be the functional product of the
BIC non-coding RNA, which is highly expressed in human lym-
phoma samples (Eis et al., 2005). MiR-155 has been shown to
play a role in B cell (Rodriguez et al., 2007; Thai et al., 2007;
Vigorito et al., 2007; Teng et al., 2008), T cell (Kohlhaas et al.,
2009; O’Connell et al., 2010a), dendritic cell (Lu et al., 2011a),
and macrophage (O’Connell et al., 2007) biology, particularly in
the context of activation. While miR-155 is modestly expressed in
resting peripheral mouse and human NK cells, its expression is
markedly increased by activation with IL-18 (Fehniger et al., 2010;
Trotta et al., 2012; Sullivan, Leong, and Fehniger unpublished
data). Recently, Trotta et al. (2012) reported miR-155 as a posi-
tive regulator of NK IFN-γ production following IL-12 and IL-18
stimulation of human NK cells and lines that were transduced
with lentivirus to over-express miR-155. This effect was reported
to be mediated through direct repression of Src homology 2
domain-containing inositol-5-phosphatase 1 (SHIP-1; O’Connell
et al., 2009), an established negative regulator of IFN-γ production
(Trotta et al., 2012). Additional studies clarifying the in vivo mech-
anistic role of miR-155, especially in the context of in vivo infection
and tumor models, will be of high interest. In addition, other
miR-155 questions still remain unanswered: is SHIP-1 the only
target of miR-155? Are there different mRNA targets before and
after cytokine activation? Thus, while miR-155 has a clear role in
regulating IFN-γ production, and targets SHIP-1, other roles for
miR-155 inNK cell effector function remain open to investigation.
The miR-29a/b/c family is moderately expressed in resting NK
cells (Fehniger et al., 2010), and has been shown to regulate the
IFN-γ pathway by two independent laboratories (Ma et al., 2011;
Steiner et al., 2011). However, these studies differ in their proposed
mechanisms of regulation. Indeed, the two studies identify two
unique targets for miR-29. Steiner et al. (2011) showed, through
an extensive miRNA screening approach, that at least in CD4+ T
cells, miR-29’s regulation of IFN-γ production was indirect, via
targeting Tbx21 (T-bet) and Eomes, two important transcription
factors that induce IFN-γ mRNA. In contrast, Ma et al. (2011)
created an in vivo sponge model targeting the miR-29 family. The
result of this “sponge,” which prevents miR-29 from binding to its
usual targets, resulted in increased IFN-γ protein production (Ma
et al., 2011). Further, through in vitro testing, the group showed
that this regulation of IFN-γwas direct, and that T-bet and Eomes
were not targets of miR-29. Additional in vitro studies by our lab in
293T cells utilizing luciferase sensor-plasmids failed to conﬁrm the
murine IFN-γ 3′UTR as a direct target of miR-29, while validating
targeting of T-bet and Eomes (Sullivan et al., 2012; Sullivan and
Fehniger, unpublished). Further study will be required to clarify
the precise role of miR-29 in IFN-γ regulation in NK cells using
NK cell-speciﬁc genetic models.
The miR-15/16 family is encoded from two distinct loci in the
genome, miR-15a/16-1 and miR-15b/16-2, which are processed
to three mature miRNAs: miR-15a, miR-15b, and miR-16. This
family has been implicated in the development or progression
of several malignancies, including chronic lymphocytic leukemia
(Klein et al., 2010; Iorio and Croce, 2012). Additionally, they have
been shown to regulate cell survival and cell cycle progression
through regulation of Bcl2 and cyclin D1, respectively (Cimmino
et al., 2005; Oﬁr et al., 2011). All members of the miR-15/16 fam-
ily are highly expressed in NK cells, suggesting that transcription
operates from both loci (Fehniger et al., 2010). These family mem-
bers are predicted through bioinformatic algorithms to target the
murine IFN-γ 3′UTR, which was conﬁrmed in vitro by luciferase
sensor-plasmid experiments (Sullivan et al., 2012). Furthermore,
mature miRNAs from this family are down-regulated in primary
NK cells after activation with IFN-γ stimulating conditions. While
these ﬁndings suggest that the miR-15/16 family of miRNAs may
be key players in regulating NK cell IFN-γ production, additional
studies utilizing in vitro and in vivo loss- and gain-of-function will
be required to deﬁne the non-redundant role of thismiRNA family
on NK cell IFN-γ production.
NK CELL miRNAs IN DISEASE
Natural killer cells are primarily deﬁned by their role in prevent-
ing disease and malignancy through recognition of target cells
(Orange and Ballas, 2006), and a large and growing body of
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literature on the miRNA-mediated regulation of NK cell receptor
ligands on target cells has been extensively covered elsewhere (Elias
andMandelboim,2012). However, dysregulatedNKcells can cause
or participate in a wide variety of diseases, including hemophago-
cytic lymphohistiocytosis (Filipovich, 2009), pre-eclampsia (Riley
and Yokoyama, 2008), atopy, and autoimmunity, among others.
Data for the role for NK cell-intrinsic miRNA in these diseases is
limited, but an important area of active investigation. For exam-
ple, it was recently found that in patients with chronic fatigue
syndrome, certain highly expressed NK miRNAs, such as miR-
21, were signiﬁcantly decreased in NK cells (Brenu et al., 2012).
Most of the existing literature regarding the role of NK miRNAs
in disease focuses on NK cell malignancies. Rare cancers aris-
ing from NK cells can take multiple forms with various degrees
of aggression, from chronic NK cell lymphocytosis, to aggres-
sive nasal-type NK/T cell lymphoma, to highly aggressive NK cell
leukemia/lymphoma (Ishida andKwong,2010;Watters et al., 2011;
Semenzato et al., 2012).
Several reports have shown dysregulated miRNA levels in NK
cellmalignancies. Yamanaka et al. (2009) reported over-expression
of both miR-21 and/or miR-155 in malignant NK cell lines as well
as primary patient samples. The authors further linked miR-21 to
phosphatase and tensin homolog (PTEN) and miR-155 to SHIP-1,
two well known tumor regulators, the suppression of which could
enhance cancer progression (Yamanaka et al., 2009). In contrast,
Ng et al. (2011) showed that in nasal-typeNK/T lymphomas,miR-
NAs (miR-26a/b, miR-28-5p, miR-101, miR-146a, miR-363) were
predominantly down-regulated. Whether or not this is an impor-
tant biological difference between nasal-type NK/T lymphomas
and the more aggressive NK cell leukemia/lymphoma remains
to be established. Decreased expression of miR-146a was also
found to be a poor prognostic factor in NK/T lymphoma by Paik
et al. (2011). The authors suggest that this occurs via miR-146a
suppression of tumor necrosis factor receptor-associated factor
6 (TRAF6), which is a target of miR-146a. miRNAs produced
by Epstein–Barr virus (EBV) may be involved in the transforma-
tion leading to the aggressive NK cell lymphoma. Ramakrishnan
et al. (2011) proﬁled NK cell lymphoma cell lines, and found
that EBV-encoded miRNAs (BART-7, BART-9, BART-17-5p) were
abundantly expressed, and that loss of these miRNAs resulted in
reduced cell division rates. However, these intriguing results were
highly dependent on the cell line chosen, and require conﬁrmation
in additional cell lines as well as primary samples. Further studies
will also be required to determine the requirement, if any, for EBV-
encoded miRNAs in the pathogenesis of EBV-infected NK tumor
cells. In a recent study from the Caligiuri laboratory the mecha-
nisms whereby chronic exposure to high levels of IL-15 may lead
to large granule lymphocyte (LGL) leukemia were deﬁned. Exces-
sive IL-15 signals led to Myc-mediated suppression of miR-29b,
in turn leading to Dnmt3b over-expression and DNA hyperme-
thylation (Mishra et al., 2012). The authors showed that miR-29b
inhibition directly led to increased LGL transformation in a cell
line system. Furthermore, using liposomal bortezomib (a protea-
some inhibitor), the authors were able to dramatically enhance the
levels of miR-29b, which was correlated with decreased Dnmt3b
expression and disease-free survival in ICR-SCID mice that were
normally 100% susceptible to LGL leukemia. These studies directly
implicate loss of miR-29b in causing LGL leukemia with rescue
of miR-29b levels resulting in resolution of disease. Thus, this
provides the rationale for studying miR-29 mimetics as a novel
miRNA-based therapy for this disease.
There remain many unanswered questions in how miRNA dys-
regulation may lead to disease. For each of the miRNAs putatively
involved in NK cell disease pathogenesis, it will be important to
study the role of these miRNAs in primary cells and model organ-
isms using both genetic gain and loss of miRNA function in order
to address the mechanism of miRNA function. As of now, much
of the data for miRNA involvement in disease is correlative, but if
miRNA alterations are shown to cause or contribute to pathogen-
esis or disease progression, there exists great potential for targeting
using miRNA mimics or silencers in vivo.
miRNA TARGET DETERMINATION IN NK CELLS
miRNA biogenesis is regulated at multiple levels, and private com-
ponents have been identiﬁed that may control individual miRNA
expression levels (Kim, 2005; Winter et al., 2009). Further, many
miRNAs exist in families, with closely related members that share
key binding speciﬁcity sequences, including the “seed” sequence,
from base pairs 2–8 (5′ → 3′) of the mature miRNA, that is the
major determinant of target speciﬁcity (Garcia et al., 2011). These
families of miRNAs are thought to cooperate in their regulation
of target genes, and thus loss-of-function models can be difﬁ-
cult, as one must account for all expressed family members of a
given family. In order to avoid this complexity, miRNA “sponges”
that sequester whole miRNA families can be transgenically intro-
duced; however, it is possible that introducing a foreign small RNA
sequence could have unintended or off-target consequences.
miRNAs can be computationally predicted to bind to hun-
dreds of target mRNAs (Lewis et al., 2003), but these predictions
are prone to false positive and negatives, and thus it is critical to
biochemically and biologically validate predicted miRNA:mRNA
target interactions. In addition, multiple disparate mature miR-
NAs likely regulate the samemRNAvia distinct and/or overlapping
3′UTR binding sites, and it remains unclear how these multiple
sites interact. A plethora of miRNA target determination tools
have become available over the past few years, including bioinfor-
matic algorithms such as TargetScan1, Ensembl MicroCosm2, and
others (Wang, 2008). These tools are useful in developing initial
hypotheses about the role of individual miRNAs in cellular func-
tion, but have a high percentage of false positives (Neilson et al.,
2007; Sullivan, Leong, and Fehniger, unpublished data); i.e., many
“targets” determined by bioinformatic algorithms may not be true
targets in vitro or in vivo. An ostensibly straightforward molecular
biology experiment to determine if a gene is targeted by a miRNA
is to transduce a target cell type with the miRNA of interest, and
observe a down-regulation at a protein level via western blot or
equivalent method. However, this approach is complicated in NK
cells by the difﬁculty in reproducibly introducing foreignRNA into
resting NK cells, as well as off-target effects of miRNA that may
result in the observed repression being an indirect, rather than
direct effect. Therefore, though prediction methods and in vitro
1http://www.targetscan.org/
2http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/
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FIGURE 4 | Schema of Argonaute/RISC immunoprecipitation procedure and analysis.
transduction can be useful for hypothesis generation, they are sur-
prisingly limited in their ability to validate in vivo miRNA:mRNA
interactions.
Besides the obvious beneﬁt of phenotype conﬁrmation, cre-
ation of amiRNA-knockout or transgenicmousemodel grants the
opportunity to use a variety of techniques to conﬁrm individual
miRNA targeting of speciﬁc genes. Argonaute immunoprecipi-
tation is one effective method of screening for the effects of an
individual miRNA on a speciﬁc cell type (Karginov et al., 2007;
Chi et al., 2009; Matkovich et al., 2011). In this method, both
total RNA and RNA immunoprecipitated using anti-Argonaute
(a component of the RISC) antibodies, and are sequenced
(using next-generation sequencing approaches) and aligned to the
genome (Figure 4). miRNA-knockout or miRNA-over-expressing
NK cells can be compared to WT NK cells for their RISC-bound
(Figure 1) RNA “proﬁle,” as well as their total RNA proﬁle. While
controversy still exists in the ﬁeld over the relative contribution
of miRNA to transcript degradation or translational inhibition
(Ambros, 2004; He and Hannon, 2004; Liu, 2008; Selbach et al.,
2008), a combination of assessing total RNA changes and RISC-
incorporation changes can determine, at a functional level, the
role of an individual miRNA in targeting. This technique has yet
to be applied to NK cells, and will likely unveil very interesting
ﬁndings.
Predicted miRNA targeting of an mRNA can also be biochemi-
cally validated,most commonly using a luciferase“sensor plasmid”
reporter system. In this system, the 3′UTR of a putative target gene
is fused to luciferase. This construct is then transfected into a cell
line, such as HEK293T, while co-transfecting another vector that
over-expresses or inhibits the miRNA of interest. If a miRNA tar-
gets the 3′UTR of interest, this is experimentally measured by a
decrease in luciferase activity. This approach, while useful, has a
number of caveats, and it is important to be cognizant of potential
confounders in this system. Proper controls and veriﬁcations must
be included, including (1) validation of miRNA over-expression,
(2) use of a luciferase vector with no 3′UTR to determine “base-
line” targeting of the vector, (3) normalization of the luciferase
signal to control for transfection efﬁciency differences between
different luciferase constructs, and (4) mutation of the putative
miRNA binding site in the 3′UTR in order to demonstrate that
loss of this predicted site results in loss of miRNA-mediated repres-
sion. The last issue, mutating the predicted binding site, is critical
to demonstrate a direct targeting event. In our experiments, the
psiCheck2 vector (Promega) has performed consistently and effec-
tively. The use of a non-NK cell to evaluate a mRNA:miRNA
targeting interaction is a reasonable ﬁrst step in validating that
the miRNA targets the given mRNA. In fact, since some miRNAs
that are highly expressed in NK cells are not highly expressed in
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293T cells, these miRNAs may be more easily over-expressed and
otherwise manipulated, allowing one to more easily observe the
effects of miRNA over-expression on that speciﬁc target. How-
ever, similar to most functional aspects of NK cell biology, it is
critical to validate a given miRNA:mRNA targeting event in pri-
mary NK cells, since there is the possibility that certain effects of
miRNAs require inducible machinery that is unique to NK cells.
This requires speciﬁc miRNA mouse genetic models or in vitro
mediated gain- and loss-of-function, paired with evaluation of
the speciﬁc miRNA-mediated phenotype in primary NK cells.
CONCLUSION
miRNAs are a class of non-coding RNAs that have increasingly
been shown to be critical to NK gene regulation. Recently, the
NK cell ﬁeld has become acquainted with the miRNA expression
proﬁle of murine and human NK cells, the global role of miRNAs
in NK cell biology, and the inﬂuence of a few individual miRNAs
on the NK cell molecular program in homeostasis as well as dis-
ease states. However, with over 60 highly expressed miRNAs in NK
cells, there is still much work to do to dissect the function of each
individual miRNA in these unique immune cells.
ACKNOWLEDGMENTS
The authors wish to thank M. Cooper, as well as members of
the Todd A. Fehniger laboratory for providing comments on this
review, and to also express sincere regrets to those authors whose
work could not be included due to space restrictions. This work
was supported by NIH T32HL708836 to Ryan P. Sullivan, and the
American Society of Hematology, the Howard Hughes Medical
Institute, and NIH K08HL093299 to Todd A. Fehniger.
REFERENCES
Allantaz, F., Cheng, D. T., Bergauer, T.,
Ravindran, P., Rossier, M. F., Ebel-
ing, M., et al. (2012). Expression
proﬁling of human immune cell sub-
sets identiﬁes miRNA–mRNA regu-
latory relationships correlated with
cell type speciﬁc expression. PLoS
ONE 7:e29979. doi: 10.1371/jour-
nal.pone.0029979
Ambros, V. (2004). The functions
of animal microRNAs. Nature 431,
350–355.
Bachanova, V., McCullar, V., Lenvik,
T., Wangen, R., Peterson, K. A.,
Ankarlo, D. E. M., et al. (2009).
Activated notch supports develop-
ment of cytokine producing NK cells
which are hyporesponsive and fail to
acquire NK cell effector functions.
Biol. Blood Marrow Transplant. 15,
183–194.
Beck, R. C., Padival, M., Yeh, D., Ral-
ston, J., Cooke, K. R., and Lowe, J. B.
(2009). The Notch ligands Jagged2,
Delta1, and Delta4 induce differen-
tiation and expansion of functional
human NK cells from CD34+ cord
blood hematopoietic progenitor cells.
Biol. Blood Marrow Transplant. 15,
1026–1037.
Bezman, N. A., Cedars, E., Steiner, D.
F., Blelloch, R., Hesslein, D. G. T.,
and Lanier, L. L. (2010). Distinct
requirements of microRNAs in NK
cell activation, survival, and function.
J. Immunol. 185, 3835–3846.
Bezman, N. A., Chakraborty, T., Bender,
T., and Lanier, L. L. (2011). miR-
150 regulates the development of NK
and iNKT cells. J. Exp. Med. 208,
2717–2731.
Brenu, E.W.,Ashton,K. J., vanDriel,M.,
Staines, D. R., Peterson, D., Atkinson,
G. M., et al. (2012). Cytotoxic lym-
phocyte microRNAs as prospective
biomarkers for chronic fatigue syn-
drome/myalgic encephalomyelitis. J.
Affect. Disord. 141, 261–269.
Bryceson, Y. T., and Long, E. O. (2008).
Line of attack: NK cell speciﬁcity and
integration of signals. Curr. Opin.
Immunol. 20, 344–352.
Caligiuri, M. A. (2008). Human natural
killer cells. Blood 112, 461–469.
Chaix, J., Tessmer, M. S., Hoebe, K.,
Fuséri, N., Ryffel, B., Dalod, M.,
et al. (2008). Cutting edge: priming
of NK cells by IL-18. J. Immunol. 181,
1627–1631.
Chen, C.-Z., Li, L., Lodish, H. F.,
and Bartel, D. P. (2004). MicroR-
NAs modulate hematopoietic lin-
eage differentiation. Science 303,
83–86.
Chi, S. W., Zang, J. B., Mele, A., and
Darnell, R. B. (2009). Argonaute
HITS-CLIP decodes microRNA-
mRNA interaction maps. Nature 460,
479–486.
Chiossone, L., Chaix, J., Fuseri,N., Roth,
C., Vivier, E., and Walzer, T. (2009).
Maturation of mouse NK cells is a 4-
stage developmental program. Blood
113, 5488–5496.
Chong, M. M. W., Rasmussen, J. P.,
Rudensky,A.Y., Rundensky,A.Y., and
Littman, D. R. (2008). The RNAseIII
enzyme Drosha is critical in T cells
for preventing lethal inﬂammatory
disease. J. Exp. Med. 205, 2005–2017.
Cichocki, F., Felices, M., McCullar, V.,
Presnell, S. R., Al-Attar, A., Lutz,
C. T., et al. (2011). Cutting edge:
microRNA-181 promotes human NK
cell development by regulating notch
signaling. J. Immunol. 187, 6171–
6175.
Cimmino, A., Calin, G. A., Fabbri, M.,
Iorio, M. V., Ferracin, M., Shimizu,
M., et al. (2005). miR-15 and miR-16
induce apoptosis by targeting BCL2.
Proc. Natl. Acad. Sci. U.S.A. 102,
13944–13949.
Colucci, F., Caligiuri, M. A., and Di
Santo, J. P. (2003). What does it take
to make a natural killer? Nat. Rev.
Immunol. 3, 413–425.
de Boer, J., Williams, A., Skavdis, G.,
Harker, N., Coles, M., Tolaini, M.,
et al. (2003). Transgenic mice with
hematopoietic and lymphoid speciﬁc
expression of Cre. Eur. J. Immunol.
33, 314–325.
Di Santo, J. P. (2006). Natural killer cell
developmental pathways: a question
of balance. Annu. Rev. Immunol. 24,
257–286.
Di Santo, J. P. (2008). Natural killer cells:
diversity in search of a niche. Nat.
Immunol. 9, 473–475.
Eckelhart, E., Warsch, W., Zebedin, E.,
Simma, O., Stoiber, D., Kolbe, T.,
et al. (2011). AnovelNcr1-Cremouse
reveals the essential role of STAT5 for
NK-cell survival and development.
Blood 117, 1565–1573.
Eis, P. S., Tam, W., Sun, L., Chadburn,
A., Li, Z., Gomez, M. F., et al. (2005).
Accumulation of miR-155 and BIC
RNA in human B cell lymphomas.
Proc. Natl. Acad. Sci. U.S.A. 102,
3627–3632.
Elias, S., and Mandelboim, O.
(2012). Battle of the midgets: innate
microRNA networking. RNA Biol. 9,
792–798.
Fehniger, T. A., Cai, S. F., Cao, X., Bre-
demeyer, A. J., Presti, R. M., French,
A. R., et al. (2007). Acquisition of
murine NK cell cytotoxicity requires
the translation of a pre-existing pool
of granzyme B and perforin mRNAs.
Immunity 26, 798–811.
Fehniger, T. A., Wylie, T., Ger-
mino, E., Leong, J. W., Magrini,
V. J., Koul, S., et al. (2010). Next-
generation sequencing identiﬁes the
natural killer cell microRNA tran-
scriptome. Genome Res. 20, 1590–
1604.
Filipovich, A. H. (2009). Hemopha-
gocytic lymphohistiocytosis (HLH)
and related disorders. Hematology
2009, 127–131.
Filipowicz, W., Bhattacharyya, S.
N., and Sonenberg, N. (2008).
Mechanisms of post-transcriptional
regulation by microRNAs: are the
answers in sight? Nat. Rev. Genet. 9,
102–114.
Freud, A. G., and Caligiuri, M. A.
(2006). Human natural killer cell
development. Immunol. Rev. 214,
56–72.
Garcia, D. M., Baek, D., Shin, C., Bell,
G. W., Grimson, A., and Bartel, D.
P. (2011). Weak seed-pairing stabil-
ity and high target-site abundance
decrease the proﬁciency of lsy-6 and
other microRNAs. Nat. Struct. Mol.
Biol. 18, 1139–1146.
Ghisi, M., Corradin, A., Basso, K.,
Frasson, C., Seraﬁn, V., Mukher-
jee, S., et al. (2011). Modulation
of microRNA expression in human
T-cell development: targeting of
NOTCH3 by miR-150. Blood 117,
7053–7062.
Gong, J., Liu, R., Zhuang, R., Zhang,
Y., Fang, L., Xu, Z., et al. (2012).
miR-30c-1* promotes natural killer
cell cytotoxicity against human hep-
atoma cells by targeting the transcrip-
tion factor HMBOX1. Cancer Sci.
103, 645–652.
Haraguchi, K., Suzuki, T., Koyama,
N., Kumano, K., Nakahara, F., Mat-
sumoto, A., et al. (2009). Notch
activation induces the generation of
functional NK cells from human cord
blood CD34-positive cells devoid
of IL-15. J. Immunol. 182, 6168–
6178.
He, L., and Hannon, G. J. (2004).
MicroRNAs: small RNAs with a big
role in gene regulation. Nat. Rev.
Genet. 5, 522–531.
Hesslein, D. G. T., and Lanier, L. L.
(2011). Transcriptional control of
natural killer cell development and
function. Adv. Immunol. 109, 45–85.
Huang, Y., Lei, Y., Zhang, H., Hou, L.,
Zhang, M., and Dayton, A. I. (2011).
MicroRNA regulation of STAT4 pro-
tein expression: rapid and sensitive
Frontiers in Immunology | NK Cell Biology February 2013 | Volume 4 | Article 44 | 10
“ﬁmmu-04-00044” — 2013/2/26 — 16:00 — page 11 — #11
Sullivan et al. MicroRNA regulation of natural killer cells
modulation of interleukin-12 signal-
ing in human natural killer cells.
Blood 118, 6793–6802.
Iorio, M. V., and Croce, C. M. (2012).
MicroRNA dysregulation in cancer:
diagnostics, monitoring and ther-
apeutics. A comprehensive review.
EMBO Mol. Med. 4, 143–159.
Ishida, F., and Kwong, Y.-L. (2010).
Diagnosis and management of natu-
ral killer-cell malignancies. Exp. Rev.
Hematol. 3, 593–602.
Jiang, S., Li, C., Olive, V., Lykken,
E., Feng, F., Sevilla, J., et al. (2011).
Molecular dissection of the miR-17-
92 cluster’s critical dual roles in pro-
moting Th1 responses and prevent-
ing inducible Treg differentiation.
Blood 118, 5487–5497.
Johnnidis, J. B., Harris, M. H., Wheeler,
R. T., Stehling-Sun, S., Lam, M. H.,
Kirak, O., et al. (2008). Regulation
of progenitor cell proliferation and
granulocyte function by microRNA-
223. Nature 451, 1125–1129.
Joncker, N. T., and Raulet, D. H. (2008).
Regulation of NK cell responsiveness
to achieve self-tolerance and maxi-
mal responses to diseased target cells.
Immunol. Rev. 224, 85–97.
Jonsson, H. A., and Yokoyama, W. M.
(2009). Natural killer cell tolerance
licensing and othermechanisms.Adv.
Immunol. 101, 27–79.
Karginov, F. V., Conaco, C., Xuan, Z.,
Schmidt, B. H., Parker, J. S., Man-
del, G., et al. (2007). A biochemical
approach to identifying microRNA
targets. Proc. Natl. Acad. Sci. U.S.A.
104, 19291–19296.
Khabar, K. S. A., and Young, H. A.
(2007). Post-transcriptional control
of the interferon system. Biochimie
89, 761–769.
Kim, T.-D., Lee, S. U. H., Yun, S., Sun,
H., Kim, J. W., Kim, H. M., et al.
(2011). Human microRNA-27a * tar-
gets Prf1 and GzmB expression to
regulate NK cell cytotoxicity. Blood
118, 5476–5486.
Kim, V. N. (2005). MicroRNA biogene-
sis: coordinated cropping and dicing.
Nat. Rev. Mol. Cell Biol. 6, 376–385.
Klein, U., Lia, M., Crespo, M., Siegel, R.,
Shen, Q., Mo, T., et al. (2010). The
DLEU2/miR-15a/16-1 cluster con-
trols B cell proliferation and its dele-
tion leads to chronic lymphocytic
leukemia. Cancer Cell 17, 28–40.
Kohlhaas, S., Garden, O. A., Scudamore,
C., Turner, M., Okkenhaug, K., and
Vigorito, E. (2009). Cutting edge: the
Foxp3 target miR-155 contributes to
the development of regulatory T cells.
J. Immunol. 182, 2578–2582.
Landgraf, P., Rusu, M., Sheridan, R.,
Sewer, A., Iovino, N., Aravin, A., et al.
(2007). A mammalian microRNA
expression atlas based on small RNA
library sequencing. Cell 129, 1401–
1414.
Lanier, L. L. (2005). NK cell recognition.
Annu. Rev. Immunol. 23, 225–274.
Lanier, L. L. (2008). Upon the tightrope:
natural killer cell activation and inhi-
bition. Nat. Immunol. 9, 495–502.
Lee, S.-H., Miyagi, T., and Biron, C. A.
(2007). Keeping NK cells in highly
regulated antiviral warfare. Trends
Immunol. 28, 252–259.
Lewis, B. P., Shih, I., Jones-Rhoades,
M. W., Bartel, D. P., and Burge, C.
B. (2003). Prediction of mammalian
microRNA targets. Cell 115, 787–798.
Li, Q.-J., Chau, J., Ebert, P. J. R.,
Sylvester, G., Min, H., Liu, G.,
et al. (2007). miR-181a is an intrin-
sic modulator of T cell sensitivity and
selection. Cell 129, 147–161.
Liu, J. (2008). Control of protein syn-
thesis and mRNA degradation by
microRNAs. Curr. Opin. Cell Biol. 20,
214–221.
Liu, X.,Wang,Y., Sun,Q.,Yan, J.,Huang,
J., Zhu, S., et al. (2012). Identiﬁcation
of microRNA transcriptome involved
in human natural killer cell activa-
tion. Immunol. Lett. 143, 208–217.
Lu, C., Huang, X., Zhang, X., Roen-
sch, K., Cao, Q., Nakayama, K. I.,
et al. (2011a). miR-221 and miR-155
regulate human dendritic cell devel-
opment, apoptosis, and IL-12
production through targeting of
p27kip1, KPC1, and SOCS-1. Blood
117, 4293–4303.
Lu, T. X., Hartner, J., Lim, E.-J., Fabry,
V., Mingler, M. K., Cole, E. T.,
et al. (2011b). MicroRNA-21 limits
in vivo immune response-mediated
activation of the IL-12/IFN-γamma
pathway, Th1 polarization, and the
severity of delayed-type hypersensi-
tivity. J. Immunol. 187, 3362–3373.
Lucas, M., Schachterle, W., Oberle,
K., Aichele, P., and Diefenbach, A.
(2007). Dendritic cells prime natural
killer cells by trans-presenting inter-
leukin 15. Immunity 26, 503–517.
Ma, F., Xu, S., Liu, X., Zhang, Q., Xu, X.,
Liu, M., et al. (2011). The microRNA
miR-29 controls innate and adap-
tive immune responses to intracel-
lular bacterial infection by target-
ing interferon-γ. Nat. Immunol. 12,
861–869.
Matkovich, S. J., Van Booven, D. J.,
Eschenbacher, W. H., and Dorn, G.
W. (2011). RISC RNA sequencing
for context-speciﬁc identiﬁcation of
in vivo microRNA targets. Circ. Res.
108, 18–26.
Mishra, A., Liu, S., Sams, G. H., Cur-
phey, D. P., Santhanam, R., Rush, L.
J., et al. (2012). Aberrant overexpres-
sion of IL-15 initiates large granular
lymphocyte leukemia through chro-
mosomal instability and DNA
hypermethylation. Cancer Cell 22,
645–655.
Monticelli, S., Ansel, K. M., Xiao, C.,
Socci, N. D., Krichevsky, A. M., Thai,
T. H., et al. (2005). MicroRNA pro-
ﬁling of the murine hematopoietic
system. Genome Biol. 6, R71.
Muljo, S. A., Ansel, K. M., Kanel-
lopoulou, C., Livingston, D. M.,
Rao, A., and Rajewsky, K. (2005).
Aberrant T cell differentiation in the
absence of Dicer. J. Exp. Med. 202,
261–269.
Narni-Mancinelli, E., Chaix, J., Fenis,
A., Kerdiles, Y. M., Yessaad, N., Reyn-
ders, A., et al. (2011). Fate mapping
analysis of lymphoid cells express-
ing the NKp46 cell surface receptor.
Proc. Natl. Acad. Sci. U.S.A. 108,
18324–18329.
Neilson, J. R., Zheng, G. X. Y., Burge, C.
B., and Sharp, P. A. (2007). Dynamic
regulation of miRNA expression in
ordered stages of cellular develop-
ment. Genes Dev. 21, 578–589.
Ng, S.-B., Yan, J., Huang, G., Sel-
varajan, V., Tay, J. L.-S., Lin, B.,
et al. (2011). Dysregulated microR-
NAs affect pathways and targets of
biologic relevance in nasal-type nat-
ural killer/T-cell lymphoma. Blood
118, 4919–4929.
O’Connell, R. M., Chaudhuri, A. A.,
Rao, D. S., and Baltimore, D. (2009).
Inositol phosphatase SHIP1 is a pri-
mary target of miR-155. Proc. Natl.
Acad. Sci. U.S.A. 106, 7113–7118.
O’Connell, R. M., Kahn, D., Gibson,
W. S. J., Round, J. L., Scholz, R.
L., Chaudhuri, A. A., et al. (2010a).
MicroRNA-155 promotes autoim-
mune inﬂammation by enhancing
inﬂammatory T cell development.
Immunity 33, 607–619.
O’Connell, R. M., Rao, D. S., Chaud-
huri, A. A., and Baltimore, D.
(2010b). Physiological and patho-
logical roles for microRNAs in the
immune system. Nat. Rev. Immunol.
10, 111–122.
O’Connell, R. M., Taganov, K. D.,
Boldin, M. P., Cheng, G., and Bal-
timore, D. (2007). MicroRNA-155
is induced during the macrophage
inﬂammatory response. Proc. Natl.
Acad. Sci. U.S.A. 104, 1604–1609.
Oﬁr, M., Hacohen, D., and Ginsberg,
D. (2011). miR-15 and miR-16 are
direct transcriptional targets of E2F1
that limit E2F-induced proliferation
by targeting cyclin E.Mol. Cancer Res.
9, 440–447.
Orange, J. S., and Ballas, Z. K. (2006).
Natural killer cells in human health
and disease. Clin. Immunol. 118,
1–10.
Paik, J. H., Jang, J.-Y., Jeon, Y. K.,
Kim, W. Y., Kim, T. M., Heo, D.
S., et al. (2011). MicroRNA-146a
downregulates NF{kappa}B activity
via targeting TRAF6, and functions
as a tumor suppressor having strong
prognostic implications in NK/T cell
lymphoma. Clin. Cancer Res. 17,
4761–4771.
Ramakrishnan, R., Donahue, H., Gar-
cia, D., Tan, J., Shimizu, N., Rice, A.
P., et al. (2011). Epstein–Barr virus
BART9 miRNA modulates LMP1
levels and affects growth rate of
nasal NK T cell lymphomas. PLoS
ONE 6:e27271. doi: 10.1371/jour-
nal.pone.0027271
Ramirez, K., and Kee, B. L. (2010).
Transcriptional regulation of natural
killer cell development. Curr. Opin.
Immunol. 22, 193–198.
Riley, J. K., and Yokoyama, W.
M. (2008). NK cell tolerance and
the maternal-fetal interface. Am. J.
Reprod. Immunol. 59, 371–387.
Rodriguez, A., Vigorito, E., Clare,
S., Warren, M. V., Couttet, P.,
Soond, D. R., et al. (2007). Require-
ment of bic/microRNA-155 for nor-
mal immune function. Science 316,
608–611.
Rossi, R. L., Rossetti, G., Wenandy,
L., Curti, S., Ripamonti, A., Bon-
nal, R. J. P., et al. (2011). Distinct
microRNA signatures in human lym-
phocyte subsets and enforcement of
the naive state in CD4(+) T cells
by the microRNA miR-125b. Nat.
Immunol. 12, 796–803.
Selbach, M., Schwanhäusser, B., Thier-
felder, N., Fang, Z., Khanin, R., and
Rajewsky, N. (2008). Widespread
changes in protein synthesis
induced by microRNAs. Nature 455,
58–63.
Semenzato, G., Marino, F., and Zam-
bello, R. (2012). State of the art in
natural killer cell malignancies. Int. J.
Lab. Hematol. 34, 117–128.
Spits, H., and Di Santo, J. P. (2011).
The expanding family of innate lym-
phoid cells: regulators and effectors
of immunity and tissue remodeling.
Nat. Immunol. 12, 21–27.
Steiner, D. F., Thomas, M. F., Hu, J.
K., Yang, Z., Babiarz, J. E., Allen,
C. D. C., et al. (2011). MicroRNA-
29 regulates T-Box transcription fac-
tors and interferon-γ production
in helper T cells. Immunity 35,
169–181.
Storek, J., Geddes, M., Khan, F.,
Huard, B., Helg, C., Chalandon,
Y., et al. (2008). Reconstitution of
the immune system after hematopoi-
etic stem cell transplantation in
humans. Semin. Immunopathol. 30,
425–437.
www.frontiersin.org February 2013 | Volume 4 | Article 44 | 11
“ﬁmmu-04-00044” — 2013/2/26 — 16:00 — page 12 — #12
Sullivan et al. MicroRNA regulation of natural killer cells
Sullivan, R. P., Leong, J. W., Schnei-
der, S. E., Keppel, C. K. R., Ger-
mino, E., French, A. R., et al.
(2012). MicroRNA deﬁcient NK
cells exhibit decreased survival but
enhanced function. J. Immunol. 188,
3019–3030.
Teng, G., Hakimpour, P., Landgraf, P.,
Rice, A., Tuschl, T., Casellas, R.,
et al. (2008). MicroRNA-155 is a neg-
ative regulator of activation-induced
cytidine deaminase. Immunity 28,
621–629.
Thai, T.-H., Calado, D. P., Casola, S.,
Ansel, K. M., Xiao, C., Xue, Y., et al.
(2007). Regulation of the germinal
center response by microRNA-155.
Science 316, 604–608.
Thomas, M. F., Abdul-Wajid, S., Pan-
duro, M., Babiarz, J. E., Rajaram,
M., Woodruff, P., et al. (2012). Eri1
regulates microRNA homeostasis
and mouse lymphocyte development
and antiviral function. Blood 120,
130–142.
Trotta, R., Chen, L., Ciarlariello, D.,
Josyula, S., Mao, C., Costinean, S.,
et al. (2012). MiR-155 regulates IFN-
γ production in natural killer cells.
Blood 119, 3478–3485.
Vasudevan, S., Tong, Y., and Steitz, J.
A. (2007). Switching from repres-
sion to activation: microRNAs can
up-regulate translation. Science 318,
1931–1934.
Vigorito, E., Perks, K. L., Abreu-
Goodger, C., Bunting, S., Xiang,
Z., Kohlhaas, S., et al. (2007).
microRNA-155 regulates the gen-
eration of immunoglobulin class-
switched plasma cells. Immunity 27,
847–859.
Vivier, E., Tomasello, E., Baratin, M.,
Walzer, T., and Ugolini, S. (2008).
Functions of natural killer cells. Nat.
Immunol. 9, 503–510.
Wang, P., Gu, Y., Zhang, Q., Han,
Y., Hou, J., Lin, L., et al. (2012).
Identiﬁcation of resting and type
I IFN-activated human NK cell
miRNomes reveals microRNA-378
and microRNA-30e as negative reg-
ulators of NK cell cytotoxicity. J.
Immunol. 189, 211–221.
Wang, X. (2008). miRDB: a microRNA
target prediction and functional
annotation database with a wiki
interface. RNA 14, 1012–1017.
Watters, R. J., Liu, X., and Loughran, T.
P. (2011). T-cell andnatural killer-cell
large granular lymphocyte leukemia
neoplasias. Leuk. Lymphoma 52,
2217–2225.
Winter, J., Jung, S., Keller, S., Gre-
gory, R. I., and Diederichs, S.
(2009). Many roads to maturity:
microRNA biogenesis pathways and
their regulation. Nat. Cell Biol. 11,
228–234.
Wu, L., and Belasco, J. G. (2008). Let me
count the ways: mechanisms of gene
regulation by miRNAs and siRNAs.
Mol. Cell 29, 1–7.
Xiao, C., Calado, D. P., Galler, G.,
Thai, T. H., Patterson, H. C., Wang,
J., et al. (2007). MiR-150 controls B
cell differentiation by targeting the
transcription factor c-Myb. Cell 131,
146–159.
Yamanaka, Y., Tagawa, H., Taka-
hashi, N., Watanabe, A., Guo,
Y.-M., Iwamoto, K., et al. (2009).
Aberrant overexpression of microR-
NAs activate AKT signaling
via down-regulation of tumor
suppressors in natural killer-cell lym-
phoma/leukemia. Blood 114, 3265–
3275.
Yokoyama, W. M., Kim, S., and French,
A. R. (2004). The dynamic life of nat-
ural killer cells. Annu. Rev. Immunol.
22, 405–429.
Young, H. R. (1996). Regulation
of interferon-gamma gene expres-
sion. J. Interferon Cytokine Res. 568,
563–568.
Zhou, B., Wang, S., Mayr, C., Bartel, D.
P., and Lodish, H. F. (2007). miR-150,
a microRNA expressed in mature B
and T cells, blocks early B cell devel-
opment when expressed prematurely.
Proc. Natl. Acad. Sci. U.S.A. 104,
7080–7085.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 31 October 2012; accepted:
06 February 2013; published online: 28
February 2013.
Citation: Sullivan RP, Leong JW and
Fehniger TA (2013)MicroRNA regulation
of natural killer cells. Front. Immunol.
4:44. doi: 10.3389/ﬁmmu.2013.00044
This article was submitted to Frontiers in
NK Cell Biology, a specialty of Frontiers
in Immunology.
Copyright © 2013 Sullivan, Leong and
Fehniger. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Immunology | NK Cell Biology February 2013 | Volume 4 | Article 44 | 12
